Merck Reports Strong Revenue, Earnings

This is a U.S. news story, published by CNBC, that relates primarily to Keytruda news.

U.S. news

For more U.S. news, you can click here:

more U.S. news

Keytruda news

For more Keytruda news, you can click here:

more Keytruda news

drug discoveries news

For more drug discoveries news, you can click here:

more drug discoveries news

CNBC news

For more news from CNBC, you can click here:

more news from CNBC

About the Otherweb

Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about

animal health business

. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest strong sales news, Merck news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!

higher sales

CNBC

•

Merck tops earnings estimates on strong demand for Keytruda, new drugs even as HPV vaccine sales fall

Summary

Nutrition label

86% Informative

Merck on Thursday reported third-quarter revenue and adjusted earnings that topped expectations.

The company saw strong sales from its top-selling cancer drug Keytruda , recently launched treatments and its animal health business.

But Merck 's vaccine that prevents cancer from HPV , the most common sexually transmitted infection in the U.S. , posted another quarter of lighter-than-expected sales.

Revenue from the shot, Gardasil , fell 11% compared to the year-earlier period.

Merck 's animal health division, which develops vaccines and medicines for dogs, cats and cattle, posted $1.49 billion in sales for the third quarter . That is up 6% from the year-earlier period and slightly above what analysts surveyed by StreetAccount were expecting..

VR Score

Informative language

Neutral language

Article tone

formal

Language

English

Language complexity

Offensive language

not offensive

Hate speech

not hateful